2024-03-28T11:02:07Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00022971
2023-01-16T04:11:31Z
499:500:501
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer
Kanda, Mitsuro
67807
Shimizu, Dai
67808
Fujii, Tsutomu
67809
Tanaka, Haruyoshi
67810
Shibata, Masahiro
67811
Iwata, Naoki
67812
Hayashi, Masamichi
67813
Kobayashi, Daisuke
67814
Tanaka, Chie
67815
Yamada, Suguru
67816
Nakayama, Goro
67817
Sugimoto, Hiroyuki
67818
Koike, Masahiko
67819
Fujiwara, Michitaka
67820
Kodera, Yasuhiro
67821
Identification of novel gastric cancer (GC)-related molecules is necessary to improve management of patients with GC in both diagnostic and therapeutic aspects. The aim of the present study was to determine whether protein arginine methyltransferase 5 (PRMT5) acts as an oncogene in the progression of GC and whether it serves as a novel diagnostic marker and therapeutic target. We conducted global expression profiling of GC cell lines and RNA interference experiments to evaluate the effect of PRMT5 expression on the phenotype of GC cells. We analysed tissues of 179 patients with GC to assess the association of PRMT5 mRNA levels with clinicopathological factors. Differential expression of PRMT5 mRNA by GC cell lines correlated positively with the levels of GEMIN2, STAT3 and TGFB3. PRMT5 knockdown reduced the proliferation, invasion and migration of a GC cell line. PRMT5 mRNA levels were significantly higher in GC tissues than the corresponding adjacent normal tissues and were independent of tumour depth, differentiation and lymph node metastasis. High PRMT5 expression was an independent risk factor of positive peritoneal lavage cytology (odds ratio 3.90, P=0.003) and decreased survival. PRMT5 enhances the malignant phenotype of GC cell lines and its expression in gastric tissues may serve as a biomarker for patient stratification and a potential target of therapy.
journal article
Spandidos Publications
2016-09
application/pdf
International Journal of Oncology
3
49
1195
1202
http://doi.org/10.3892/ijo.2016.3584
http://hdl.handle.net/2237/25152
1019-6439
https://nagoya.repo.nii.ac.jp/record/22971/files/PRMT5-MK_2016_IJO.pdf
eng
https://doi.org/10.3892/ijo.2016.3584